Press Releases Year None2020201920182017 July 22, 2020 SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors PDF Version June 22, 2020 BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial PDF Version June 22, 2020 SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma PDF Version June 2, 2020 SpringWorks Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference PDF Version May 26, 2020 SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors PDF Version May 12, 2020 SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights PDF Version March 18, 2020 SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 PDF Version March 12, 2020 SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights PDF Version February 27, 2020 MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors PDF Version February 18, 2020 SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last »
July 22, 2020 SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors PDF Version
June 22, 2020 BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial PDF Version
June 22, 2020 SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma PDF Version
June 2, 2020 SpringWorks Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference PDF Version
May 26, 2020 SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors PDF Version
May 12, 2020 SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights PDF Version
March 18, 2020 SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 PDF Version
March 12, 2020 SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights PDF Version
February 27, 2020 MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors PDF Version
February 18, 2020 SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference PDF Version
